Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 16, Pages 8994
Publisher
MDPI AG
Online
2021-08-23
DOI
10.3390/ijms22168994
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study
- (2021) Matteo Casale et al. CLINICAL DRUG INVESTIGATION
- Therapeutic assessment of combination therapy with a neprilysin inhibitor and angiotensin type 1 receptor antagonist on angiotensin II-induced atherosclerosis, abdominal aortic aneurysms, and hypertension
- (2021) Yasir Alsiraj et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model
- (2021) Wen-Han Cheng et al. CARDIOVASCULAR DRUGS AND THERAPY
- New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
- (2021) Martin Aguilar et al. CARDIOVASCULAR RESEARCH
- The Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients with Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction
- (2021) Kieran F. Docherty et al. CIRCULATION
- Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics
- (2021) Karola S. Jering et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure with Preserved Ejection Fraction
- (2021) Senthil Selvaraj et al. Journal of the American Heart Association
- Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction
- (2021) Merrill Thomas et al. ESC Heart Failure
- Natriuretic peptide receptor B maintains heart rate and sinoatrial node function via cyclic GMP-mediated signalling
- (2021) Tristan W Dorey et al. CARDIOVASCULAR RESEARCH
- Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia
- (2021) Yung-Nan Tsai et al. Journal of Cardiology
- Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation
- (2020) Lu-yi-fei Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model
- (2020) Po-Cheng Chang et al. JOURNAL OF CARDIAC FAILURE
- Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies
- (2020) Henry Sutanto et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
- (2020) Vincenzo Russo et al. Journal of Clinical Medicine
- Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
- (2020) Shao-Jung Hsu et al. Pharmaceutics
- Effects of LCZ696 on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials
- (2020) Qiang Geng et al. CARDIOLOGY
- Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
- (2020) Danial Sharifi Kia et al. Journal of the American Heart Association
- Sacubitrilat reduces pro‐arrhythmogenic sarcoplasmic reticulum Ca 2+ leak in human ventricular cardiomyocytes of patients with end‐stage heart failure
- (2020) Jörg Eiringhaus et al. ESC Heart Failure
- Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
- (2020) Andrew P. Ambrosy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause
- (2020) Luis E. Rohde et al. JACC-Heart Failure
- Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy
- (2020) Yen‐Ling Sung et al. ESC Heart Failure
- Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials
- (2020) Francesco Spannella et al. ESC Heart Failure
- OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction
- (2020) Massimo F. Piepoli et al. EUROPEAN JOURNAL OF HEART FAILURE
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
- (2020) Muhammad Shahzeb Khan et al. JACC-Heart Failure
- The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases
- (2020) Dominique V M Verhaert et al. EUROPACE
- Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction
- (2019) Pieter Martens et al. Clinical Research in Cardiology
- LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
- (2019) Po-Cheng Chang et al. Cardiovascular Therapeutics
- Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation
- (2019) Lourdes Vicent et al. HEART AND VESSELS
- Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
- (2019) António Valentim Gonçalves et al. Journal of Clinical Medicine
- Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy
- (2019) Jun-Yu Huo et al. International Heart Journal
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
- (2019) John J. V. McMurray et al. CIRCULATION
- Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan
- (2019) Richard T. Clements et al. Circulation-Heart Failure
- Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients
- (2019) Ibrahim El-Battrawy et al. Journal of Clinical Medicine
- Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices
- (2018) Carlos de Diego et al. HEART RHYTHM
- The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure
- (2017) Francesco Rossi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers
- (2017) Yang Zhao et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE
- (2016) Scott D. Solomon et al. Circulation-Heart Failure
- The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
- (2016) Pardeep S Jhund et al. HEART
- Understanding heart failure with preserved ejection fraction: where are we today?
- (2016) L. van Heerebeek et al. Netherlands Heart Journal
- Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials
- (2016) Bojun Gong et al. BMJ Open
- Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats
- (2015) Lodi C.W. Roksnoer et al. KIDNEY INTERNATIONAL
- Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
- (2014) Kazuomi Kario et al. HYPERTENSION
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
- (2011) Laxminarayan G Hegde et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Antiarrhythmic Effects of Losartan and Enalapril in Canine Pulmonary Vein Sleeve Preparations
- (2010) Serge Sicouri et al. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
- (2010) Luis Miguel Ruilope et al. LANCET
- Protein kinase C in heart failure: a therapeutic target?
- (2009) S. S. Palaniyandi et al. CARDIOVASCULAR RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search